Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis  by Abadie, Eric et al.
Recommendations for the use of new methods to assess the efficacy of
disease-modifying drugs in the treatment of osteoarthritis
Eric Abadie†, Dominique Ethgen‡, Bernard Avouac§, Gilles Bouvenot¶, Jaime Branco\,
Olivier Bruyere††, Gonzalo Calvo‡‡, Jean-Pierre Devogelaer§§, Renee Lilianee Dreiser¶¶,
Gabriel Herrero-Beaumont\\, Andre Kahan†††, Godfried Kreutz‡‡‡, Andrea Laslop§§§,
Ernst Martin Lemmel¶¶¶, George Nuki\\\, Leo Van De Putte††††, Luc Vanhaelst‡‡‡‡ and
Jean-Yves Reginster*, On behalf of the Group for the Respect of Excellence and Ethics in Science
(GREES)
†Department of Registration and Clinical Studies, French Agency For the Safety of Health Products
(AFSSAPS), France
‡GlaxoSmithKline, Collegeville, PA 19426, USA
§Department of Rheumatology, Henri Mondor Hospital, F-94010 Creteil, France
¶Department of Clinical Trials Methodology. Faculte´ de Me´decine, F-13385 Marseille Cedex 5, France
\Unidade Reumatologia, Hospital Egas Moniz, Lisbon, Portugal
††World Health Organization Collaborating Center for Public Health Aspects of Rheumatic Diseases,
Department of Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium
‡‡Department of Clinical Pharmacology, Santa Creu, Sant Pau Hospital, Autonomous University of
Barcelona, Barcelona, Spain
§§Rheumatology Unit, UCL 5390, St-Luc University Hospital, Universite´ catholique de Louvain,
B-1200 Brussels, Belgium
¶¶2 Rue Pierre Haret, F-75009 Paris, France
\\Department of Rheumatology, Madrid, Spain
†††Universite´ de Paris V, AP-HP, Hoˆpital Cochin, Paris, France
‡‡‡BfArM, ARM, Bonn, Germany
§§§Department of Pharmacology, University of Innsbruck, A-6020 Innsbruck, Austria
¶¶¶Max Grundig Klinik, Innere Medizin/Rheumatology, Bu¨hl, Germany
\\\Rheumatic Disease Unit, Western General Hospital, Edinburgh, UK
††††Department of Rheumatology, University Medical Center Nijmegen, Nijmegen, The Netherlands
‡‡‡‡Service d’Endocrinologie, AZ VUB, Vrije Universiteit Brussel, Brussels, Belgium
Summary
Background: Recent innovations in the pharmaceutical drug discovery environment have generated new chemical entities with the potential
to become disease modifying drugs for osteoarthritis (DMOAD’s). Regulatory agencies acknowledge that such compounds may be granted
a DMOAD indication, providing they demonstrate that they can slow down disease progression; progression would be calibrated by a
surrogate for structural change, by measuring joint space narrowing (JSN) on plain X-rays with the caveat that this delayed JSN translate
into a clinical benefit for the patient. Recently, new technology has been developed to detect a structural change of the OA joint earlier than
conventional X-rays.
Objective: The Group for the Respect of Ethics and Excellence in Science (GREES) organized a working party to assess whether these new
technologies may be used as surrogates to plain x-rays for assessment of DMOADs.
Methods: GREES includes academic scientists, members of regulatory authorities and representatives from the pharmaceutical industry.
After an extensive search of the international literature, from 1980 to 2002, two experts meetings were organized to prepare a resource
document for regulatory authorities. This document includes recommendations for a possible update of guidelines for the registration of new
chemical entities in osteoarthritis.
Results: Magnetic resonance imaging (MRI) is now used to measure parameters of cartilage morphology and integrity in OA patients. While
some data are encouraging, correlation between short-term changes in cartilage structure observed with MRI and long-term radiographic or
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clinical changes are needed. Hence, the GREES suggests that MRI maybe used as an outcome in phase II studies, but that further data is
needed before accepting MRI as a primary end-point in phase III clinical trials. Biochemical markers of bone and cartilage remodelling are
being tested to predict OA and measure disease progression. Recently published data are promising but validation as surrogate end-points
for OA disease progression requires additional study. The GREES suggests that biochemical markers remain limited to ‘proof of concept’
studies or as secondary end-points in phase II and III clinical trials. However, the GREES emphasizes the importance of acquiring additional
information on biochemical markers in order to help better understand the mode of action of drugs to be used in OA. Regulatory agencies
consider that evidence of improvement in clinical outcomes is critical for approval of DMOAD. Time to total joint replacement surgery is
probably the most relevant clinical end-point for the evaluation of efficacy of a DMOAD. However, at this time, time to surgery can not be used
in clinical trials because of bias by non disease-related factors like patient willingness for surgery or economic factors. At this stage, it
appears that DMOAD should demonstrate a significant difference compared to placebo. Benefit should be measured by 3 co-primary
end-points: JSN, pain and function. Secondary end-points should include the percentage of patients who are ‘responder’ (or ‘failure’). The
definition of a ‘failure’ patient would be someone with progression of JSN>0.5 mm over a period of 2–3 years or who has a significant
worsening in pain and/or function, based on validated cut-off values. The definition of the clinically relevant cut-off points for pain and function
must be based on data evaluating the natural history of the disease (epidemiological cohorts or placebo groups from long-term studies).
These cut-offs points should reflect a high propensity, for an individual patient, to later require joint replacement.
Conclusion: GREES has outlined a set of guidelines for the development of a DMOAD for OA. Although these guidelines are subject to
change as new information becomes available, the information above is based on the present knowledge in the field with the addition of
expert opinion.
© 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction:
Due to the rapidly increasing fraction of aging people in the
World population, osteoarthritis (OA) is becoming a more
significant public health problem. Most people over age 60
will have some form of OA and about half will have
symptoms1,2. Even though significant progresses have
been made to provide short term relief of pain from OA, the
major unmet need for OA is pharmacological agents able to
stop or reverse the progression of structural damage.
Recent innovations in the pharmaceutical drug discovery
environment have generated new chemical entities (NCE’s)
with the potential to become disease modifying osteo-
arthritis drugs (DMOAD’s). Appropriate clinical trials will
have to be designed to demonstrate the favorable benefit/
risk ratio of any new compound prior to approval from a
regulatory agency for labeling as a DMOAD’s.
However, the major difficulty for potential DMOAD’s
clinical development will be to meet the current regulatory
requirements. Both European and US regulatory
guidelines3–5 specify that in order to gain a DMOAD
indication, clinical studies need to demonstrate that a new
NCE can slow down diseases structural progression as
measured by joint space narrowing (JSN) on plain X-rays
and that this delayed JSN translates into a clinical benefit
for the patients.
One of the limitations of JSN measurements is related to
the very small changes observed over time and to the high
precision error of the measurement. More recently, MRI
has been tested for measuring cartilage morphology and
integrity in OA patients6. Even though some data are
encouraging, their interpretation is still controversial.
Measurements of biochemical markers of cartilage turn-
over have also been used in an attempt to predict OA and
measure disease progression. Their future use looks
promising but their validation as surrogate endpoint for OA
disease progression will require significant additional
work7.
In this context it appears that a very relevant clinical
endpoint to evaluate the efficacy of DMOAD’s in clinical
trials would be the need for total joint replacement (TJR).
This would be analyzed using a time to event statistical
method. However and even though guidelines with specific
criteria for TJR are available in many countries, this end-
point has not been widely used so far in clinical trials. This
is consequent to the fact that the evaluation of the actual
time to the need for TJR is most often confounded by
non-disease related factors like patient willingness for
surgery or local economic factors and health policies.
Hence, unlike other disease areas like osteoporosis where
fracture occurrence is used as a critical event for time to
event analysis, evaluation of efficacy of DMOAD’s relies on
longitudinal measurements of continuous variables.
The objective of this paper is to try to overcome these
existing difficulties in proposing a set of criteria which could
be used as surrogates for the time to surgery for TJR.
Method
The Group for the Respect of Ethics and Excellence in
Science (GREES) ‘Section Osteoarthritis’, met in two
separate occasions in January and September 2003. The
GREES includes academic scientists with an extensive
background in the considered field (i.e. rheumatology,
public health, radiology, biochemistry, epidemiology and
health economics) members of national regulatory auth-
orities and representatives of the pharmaceutical industry.
We carried on an extensive search of the electronic
databases (Medline and Premedline, Biasis Preview
Healthstar, Cochrane Library of Randomized Controlled
Trials, Cochrane Database of Systematic Reviews, Current
Contents and EBM Reviews) from 1980 until 2002. Generic
keywords related to the thesaurus of each database were
used. Since not all data are indexed in the electronic
databases, we conducted a hand search (O.B.) of the
reference section of each of the articles retrieved by the
primary search until no new paper was found. We also
contacted GREES members (scientists or industrial
partners) active in osteoarthritis. The invited experts made
a critical analysis of the available science. The objective is
to provide European regulatory authorities with a working
document allowing to update, if needed, the guidelines for
registration of drugs in osteoarthritis.
Results
CURRENT REGULATORY GUIDELINES
Regulatory guidelines for the approval of drugs to be
used as DMOADs for the treatment of OA were published
or updated recently in the US and in Europe3,4.
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The US FDA guidelines specify that because it is widely
(but not universally) accepted, JSN improvement of hip and
knee implies cartilage preservation and will thus be
reflected in clinical benefit3. However they also state that
determining what change in JSN of the knee or hip is
clinically relevant to the patient with OA is fundamental, but
currently unknown. Hence the FDA guidelines strongly
suggest that measurements of clinical outcomes should be
collected in all trials regardless of expectations on JSN,
because their assessment is critical for the analysis of the
overall risks and benefits of the product.
In a very similar way the European CPMP guidelines4
clearly recommend the use of plain X-ray for JSN measure-
ments as a primary endpoint even though it is recognized
that the nature and magnitude of structural changes that
are likely to be clinically relevant in the long term remain
uncertain. Therefore it is requested by the regulatory
authorities3,4 that clinical endpoints such as pain, disability
or time to the need for total joint replacement (TJR) surgery
should also be assessed during clinical studies.
Overall, both US and European guidelines require
improvement of clinical outcomes to correlate to delay in
JSN progression for DMOAD approval. In other words, as
long as it is correlated to an improvement of clinical
outcomes, a delay in JSN progression is considered as an
appropriate primary endpoint and as a surrogate endpoint
for total joint replacement which is the critical event charac-
teristic of a medical treatment failure for OA It is assumed
that a delay in JSN will consequently delay the need for
total joint surgery, and can hence be interpreted as a
treatment success for DMOAD’s.
OUTCOMES OF RECENT CLINICAL TRIALS WITH DMOAD’S
Only a limited number of potential DMOAD’s have shown
a delay in JSN associated with improvements of clinical
symptoms8–11. These publications report the results
obtained after treatment of hip or knee OA patients with
diacerein and glucosamine10,11.
Diacerein, an interleukin-1 inhibitor, was shown to reduce
pain and functional impairment in patients with hip or knee
OA9. The ECHODIAH study10 evaluated the effect of
diacerein on the progression of JSN in patients with hip OA
over 3 years of therapy. The primary endpoint of the study
was the radiographic progression of OA measured at the
hip, and expressed as the proportion of patients with
radiographic JSN of at least 0.5 mm during the study
period. Even though diacerein had no effect on OA symp-
toms in this study, the percentage of patients with radio-
graphic progression was significantly lower in patients
receiving diacerein than in patients receiving placebo. In
addition the study also showed that there was a non
statistically significant trend towards fewer decisions of
total hip replacement procedures in the diacerein group as
compared to the placebo group.
Clinical studies evaluating the effect of 3 years of
glucosamine sulfate administration to patients with knee
OA also provided evidence that this compound could sig-
nificantly reduce JSN at the medial compartment of the
knee as compared to placebo11–13. In these same studies a
slight worsening in symptoms was evident at the end of the
treatment with placebo, compared to the improvement
observed after glucosamine sulfate.
Overall these clinical studies evaluating the effect of
diacerein and glucosamine on OA disease progression
have shown the feasibility of detecting a structure modify-
ing effect using plain X-ray JSN measurements. However
long term studies will need to confirm that administration
of these pharmacological agents leading to a delay in
progression of JSN could also deliver clinical beneficial
effects to the OA patients.
AVAILABLE TECHNOLOGIES TO MEASURE OA DISEASE
PROGRESSION
The outcome of the studies reported above underlines
that there is still limited understanding on how OA clinical
expression patterns are linked to longitudinal structural
changes in cartilage. Plain X-rays, MRI and biochemical
markers have been used to measure OA disease progres-
sion over time. Each one of these technologies carries
limitations.
The limitation of conventional radiography for cartilage
assessment is that it only permits an approximation of
cartilage thickness change with measurement of JSN.
Even though radiographic measures of joint space width
(JSW) changes has been recommended as primary
measure of efficacy for DMOAD’s, precision of this
measurement is quite variable and dependent on standard-
ized radiographic techniques. Small positional changes
from one measurement to the other can jeopardize repro-
ducibility of JSW measurements. The degree of flexion of
the knee determines the regions of cartilage taken into
account for the measurements. Several methods including
fluoroscopy, foot maps and positioning devices can be
used to obtain satisfactory measurements, but despite
standardization of radiographic techniques the rates of JSN
can still vary widely14,15 and lead to significant difficulties in
the management of large sample size longitudinal clinical
trials. In addition, hip and knee X-rays only provide limited
information on the status of articular and peri-articular soft
tissues which may play a significant role in OA progression
and clinical expression. Recent studies have also
shown that alterations in the condition of the menisci16
could cause radiographic JSN independently of cartilage
thinning.
Measurements of JSW at the hip seems less variable
and more reproducible when using computer assisted
methods17,18.
Magnetic resonance imaging (MRI) has been seen
recently as having potential for evaluation of joints in OA
due to its ability to evaluate morphology and integrity of the
articular cartilage. It also provides a direct image of the soft
tissues around the joint.
Significant efforts and studies have been dedicated to
use MRI as a method of quantification of cartilage volume
and thickness. For technical reasons the outcome of these
studies has not been not very satisfactory for the hip
cartilage assessment. For the knee, several studies have
shown longitudinal cartilage volume losses in the range of 3
to 7% per year in OA patients19–22. However, other studies
have not detected any changes in cartilage volume in
patients with knee OA over a 3 years time period23. More
concerning is the fact that no strong correlations have been
shown between loss of cartilage volume measured by
MRI over time and changes in X-ray JSN or in clinical
symptoms. Hence, larger longitudinal studies are still
needed to clarify the clinical relevance of MRI measured
cartilage volume in OA disease progression.
Exploration of changes in the non cartilage com-
ponents of the OA joint (e.g. synovium and effusions, bone
marrow ‘edema’) is also ongoing with MRI and may
offer opportunities for the discovery new parameters of
interest24.
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However the most promising MRI capabilities could well
be the one developed to directly evaluate the changes in
cartilage matrix components (e.g. collagen and gly-
cosaminoglycan). These approaches could be of high
interest to detect early changes in cartilage components in
response to pharmacological intervention
+ several studies have shown that MRI T2 relaxation can
be used as a qualitative assessment of collagen in the
cartilage matrix25,26.
+ one of the main constituents of cartilage which is lost in
early OA, and which one would like to replace as part of
therapeutic interventions, is the glycosaminoglycan
(GAG) component. A new technique known as
dGEMRIC (delayed Gadolinium Enhanced MRI of
Cartilage) is being developed to directly image the
GAG component in cartilage27–29.
+ another approach under investigation is sodium MRI.
The rationale of this approach is driven by the fact that
early stage of OA is primarily associated with a loss of
proteoglycan (PG) and minimal changes in collagen.
PG carries a negative fixed charge density due to its
sulfate and carboxyl groups and thereby attracts
sodium ions to maintain neutrality. Consequently,
sodium concentration can be used as an indirect
measurement of PG content. Therefore sodium MRI
of the knee has the potential for detecting early
degenerative changes in cartilage30.
The joint is a complex structure involving cartilage,
synovial tissue and bone. Alterations and destruction of
these components during progression of OA will release
fragments or biological markers specific of these tissues in
synovial fluids, blood and urine31,32. There has been
progress into the use of some of these markers for the
prediction or measurement of progression of OA, as well as
for the evaluation of response to pharmacological inter-
vention with compounds of potential DMOAD activity33,34.
The potential for reliable and responsive markers is large.
However, further work is still needed on how changes
measured in some of these biochemical markers of
cartilage turnover correlate with OA disease progression.
Discussion
Overall none of the multiple options available to measure
changes in cartilage structure and integrity over time has
given full satisfaction to assess OA disease progression.
Even though most of the measurement methods can detect
changes related to the impact of OA on cartilage and other
peri-articular tissues, these changes have not been clearly
correlated so far with beneficial outcomes for the patient.
However measurement of JSN using plain X-ray is the
most documented method to date, and this supports its use
as the method of reference for DMOAD’s efficacy evalu-
ation in phase III clinical trials. At this stage it seems that
the use of MRI or biochemical markers measurements has
to remain limited to early phases proof of concept, dose
ranging studies or as secondary endpoint in phase III
clinical studies.
Tools for clinical evaluation of symptom-modifying
drugs in OA have also been proposed but they are not
appropriate for evaluation of DMOAD therapy35.
Subsequently, the most relevant endpoint for DMOAD
phase III studies still appears to be the decision of perform-
ing a TJR procedure. The use of TJR as an event charac-
terizing treatment failure – in the same way as occurrence
of fractures is used for the clinical evaluation of antiosteo-
porotic drugs – would provide the most robust and clinically
relevant endpoint to assess the efficacy of a DMOAD.
Several attempts have been made to try to standardize
the need for hip and knee total joint replacement across
multiple countries. However these efforts are mostly dedi-
cated to better allocation of resources in daily patients care
and will not address specifically the need of validating an
endpoint which could be used in clinical trials assessing
the effect of pharmacological intervention on OA disease
progression.
Patterns of clinical expression and disease progression
are also different at the hip and at the knee and this justifies
the need for specific subset of criteria for the two locations.
The use of the occurrence of TJR as a primary endpoint
in clinical trials faces two major difficulties:
+ OA is a slow progressing disease in most of the cases,
and in the absence of a validated marker to identify
patients at risk of fast progression, the use of TJR as
an outcome measurement would raise a significant
feasibility hurdle as it would lead to study design with
several years of treatment duration and large patients
sample sizes.
+ the decision leading to a TJR procedure is not only
driven by criteria of OA severity at this same joint, but is
confounded by the patient willingness for surgery and
in many cases by the intervention of third party payers
driven by local public health policies.
Hence the identification and validation of a set of surro-
gate criteria which could provide evidence of a slower
progression of the disease in patients treated with a NCE
as compared to placebo would prove to be much useful for
clinical investigation and evaluation of DMOAD’s.
The selection of appropriate surrogate criteria for the
need to surgery must take into account the following
considerations:
+ differentiation of clinical criteria from non disease
related factors
+ sensitivity to change
+ relative evolution and characteristics of hip OA
compared to knee OA
+ relation between imaging changes and pain and
functional capabilities
The correlation between X-ray changes and clinical
outcomes (pain, function) is stronger at the hip than at the
knee.
The need for surgery is the consequence of a conserva-
tive therapy failure. Hence in studies aiming at the identifi-
cation of structure modifying properties, patients with very
symptomatic OA and advanced radiological lesions should
not be considered for clinical trials. Patients with mild to
moderate OA lesions will be included in these trials. A
treatment failure can be defined as a patient reaching a
threshold of severity (clinical or radiological) or showing an
aggravation from baseline under therapy. For an individual
patient the time from baseline up to this threshold of
severity can be considered as a theoretical time to surgery.
This approach would allow to design clinical studies using a
time to event analysis.
At this stage it appears that DMOAD’s should demon-
strate a significant difference compared to placebo or an
active control in terms of JSN, pain and function over time
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(three co-primary endpoints). Furthermore, as secondary
end-points, the percentage of ‘responders’ (or ‘failures’)
should be assessed. The definition of treatment ‘failure’ for
a patient would be either a JSN >0.5 mm over a 2–3 years
period or a significant worsening in pain and/or function
based on validated cut-off values. The definition of the
clinically relevant cut-off points for pain and function
must be based on the natural history of the disease.
These cut-off points should reflect a high propensity for an
individual patient to later require joint replacement.
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